Key points are not available for this paper at this time.
I. Introduction II. Lacassagne’s Prevention Principle: A Target and an Estrogen Antagonist III. Tamoxifen as an Antitumor Agent A. ER status and the duration of tamoxifen B. Contralateral breast cancer C. Endometrial cancer D. Conclusions IV. Selective Estrogen Receptor Modulation A. Antiestrogen activity at the ER B. Coactivators for ER C. Alternate response elements on DNA D. An alternate ER-ERβ V. Biological Basis for Tamoxifen as a Breast Cancer Preventive A. Animal models B. Bones C. Lipids D. Uterus VI. Risk Factors for Breast Cancer A. Interactions among risk factors B. Identification of candidates for chemoprevention VII. Prevention of Breast Cancer with Tamoxifen A. Royal Marsden Pilot Study B. NSABP/NCI Study C. Italian study D. Conclusions VIII. Biological Basis for Raloxifene as a Breast Cancer Preventive A. Antitumor actions B. Bones C. Lipids D. Uterus IX. Study of Tamoxifen And Raloxifene (STAR) X. The Future of Prevention
Jordan et al. (Tue,) studied this question.